Results 11 to 20 of about 1,862,216 (244)
Drug-eluting stent thrombosis [PDF]
Therapeutic Advances in Cardiovascular Disease, 2009 Stent thrombosis is a rare complication following stent implantation; if it occurs, however, it is associated with a high morbidity and mortality. Despite reduced rates of restenosis, drug-eluting stents (DES) have not reduced the incidence of stent thrombosis as compared with bare-metal stents (BMS).
Stähli, B E, Camici, G G, Tanner, F C
core +10 more sources
Second Generation Drug-Eluting Stents: A Review of the Everolimus-Eluting Platform
Clinical Medicine Insights: Cardiology, 2013 Everolimus-eluting stents (EES) represent the next generation of drug-eluting stents (DES). Important design modifications include thin strut stent backbones, less inflammatory and more biocompatible polymers, and lower drug dosing.
Matthew G. Whitbeck, Robert J. Applegate
doaj +2 more sources
A novel platinum chromium everolimus-eluting stent for the treatment of coronary artery disease
Biologics: Targets & Therapy, 2013 Johan Bennett, Christophe DuboisDepartment of Cardiovascular Diseases, University Hospitals Leuven, Leuven, BelgiumAbstract: The development of coronary stents represents a major step forward in the treatment of obstructive coronary artery disease since ...
Bennett J, Dubois C
doaj +1 more source
Drug-eluting coronary stents – focus on improved patient outcomes
Patient Related Outcome Measures, 2011 Zehra Jaffery, Amit Prasad, John H Lee, Christopher J WhiteDepartment of Cardiovascular Diseases, The John Ochsner Heart and Vascular Institute, Ochsner Clinic Foundation, New Orleans, LA, USAAbstract: The development of stent has been a major advance in
Jaffery Z, Prasad A, Lee JH, White CJ
doaj +1 more source
BMJ, 2006 Last week an expert panel of the US Food and Drug Administration (FDA) recommended that the FDA should issue warnings to doctors and patients about drug eluting coronary stents. The safety of such stents is unclear except in low risk patients. Furthermore, patients with drug eluting stents should take antiplatelet therapy for at least one year after ...
Gershlick, AH, Richardson, G
+9 more sources
Canadian Medical Association Journal, 2007 In their recent systematic review, Suzanne Ligthart and associates compared analyses of the cost-effectiveness of drug-eluting stents.[1][1] They found that in most studies in which an incremental cost-effectiveness ratio greater than $50 000 per quality-adjusted life-year was calculated the ...
E Liana, Falcone, Navdeep, Tangri
openaire +4 more sources
Vascular Health and Risk Management, 2009 R Michael Kirchner, J Dawn AbbottDepartment of Cardiology, Rhode Island Hospital, Brown Medical School, Providence, RI, USAAbstract: Drug-eluting stents (DES) have had a major impact in interventional cardiology.
R Michael Kirchner, J Dawn Abbott
doaj +1 more source
CVIR Endovascular, 2021 Background Although several clinical reports demonstrated a durable patency rate after a novel fluoropolymer-coated paclitaxel-eluting stent (Eluvia; Boston Scientific, Marlborough, MA, USA) placement, aneurysmal degeneration after drug-eluting stent ...
Takuya Tsujimura +13 more
doaj +1 more source
Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2021 Background Percutaneous coronary intervention of calcified lesions was associated with worse outcomes in the era of bare‐metal and first‐generation drug‐eluting stents. Data on percutaneous coronary intervention of calcified lesions with newer‐generation
Rayyan Hemetsberger +13 more
doaj +1 more source
Stent thrombosis and drug-eluting stents [PDF]
Journal of Cardiology, 2011 Coronary stents have been used for the treatment of patients with coronary artery disease (CAD), and significantly improved procedural safety and are associated with a lower rate of restenosis compared with balloon angioplasty alone. Drug-eluting stents (DES) have been dominant for the treatment of CAD with efficacy in significantly reducing both ...
Takayama, Tadateru +2 more
openaire +2 more sources